Purpose: To assess if ripasudil has a neuroprotective effect using mice with excitatory amino acid carrier 1 (EAAC1) deletion (EAAC1 knockout [KO] mice), a mouse model of normal tension glaucoma.
Methods: Topical administration (5 μL/day) of two different concentrations of ripasudil (0.4% and 2%) were applied to EAAC1 KO mice from 5 to 12 weeks old. Optical coherence tomography, multifocal electroretinograms, the measurement of intraocular pressure (IOP), and histopathology analyses were performed at 5, 8, and 12 weeks old. Retrograde labeling of retinal ganglion cells (RGCs), immunoblot, and immunohistochemical analyses of phosphorylated p38 mitogen-activated protein kinase (MAPK) in the retina were performed at 8 weeks old.
Results: Topical ripasudil ameliorated retinal degeneration and improved visual function in EAAC1 KO mice at both 8 and 12 weeks old. Ripasudil reduced IOP and strongly suppressed the phosphorylation of p38 MAPK that stimulates RGC death in EAAC1 KO mice.
Conclusions: These results suggest that, in addition to IOP reduction, ripasudil prevents glaucomatous retinal degeneration by neuroprotection, which is achieved by suppressing cell-death signaling pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1167/iovs.17-23276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy.
Invest Ophthalmol Vis Sci
November 2024
Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Article Synopsis
- The study aimed to explore how topical 2% ripasudil (a Rho kinase inhibitor) protects the nervous system, specifically looking at retinal ganglion cell (RGC) loss in mice exposed to increased intraocular pressure (IOP) and optic nerve damage.
- Results showed that ripasudil significantly reduced RGC axon and soma loss compared to saline-treated controls, indicating its protective effects against nerve damage.
- The findings suggest that ripasudil works by suppressing ROCK signaling pathways in the retina and optic nerve, affecting both RGCs and astrocyte responses to elevated IOP.
Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy.
BMJ Open Ophthalmol
October 2024
Ophthalmology, Stanford University, Stanford, California, USA
Article Synopsis
- The study compares the effectiveness of two surgical approaches—Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping only (DSO)—for treating Fuchs endothelial corneal dystrophy (FECD) in a clinical trial called DETECT II.
- A total of 60 patients will be randomly assigned to receive either DMEK with a placebo or DSO with a drug called ripasudil, and the main goal is to evaluate visual improvement after 12 months.
- The trial aims not only to assess visual outcomes but also to explore other factors like cost-effectiveness and the incidence of adverse events, with findings planned for dissemination in scientific publications and conferences.
Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.
Eye (Lond)
December 2024
Massachusetts Eye and Ear and Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Topical therapies targeting Rho-associated protein kinase (ROCK) signalling, such as netarsudil and ripasudil, are commonly used to lower intraocular pressure in patients with glaucoma and ocular hypertension.
- Although effective in reducing eye pressure, ROCK inhibition may lead to unintended side effects in various eye structures, both positive and negative, highlighted by a systematic review of 170 studies.
- The review identifies established effects like conjunctival hyperaemia and corneal verticillata, while also pointing out less common side effects and suggesting potential new applications for ROCK inhibitors, particularly in treating corneal issues, although more research is needed for other uses.
Effects of Ripasudil Hydrochloride on Epithelial Repair in a Mouse Cornea.
Curr Eye Res
December 2024
Department of Ophthalmology, Wakayama Medical University School of Medicine, Wakayama, Japan.
Purpose: Effect of topical administration of a Rho kinase inhibitor, ripasudil, on epithelial wound healing in a mouse cornea was investigated. Effects of treatment of cultured human corneal epithelial cell (HCEC) line and organ-cultured corneal epithelium with ripasudil on expression of p-ERK was also examined.
Methods: Epithelial defects with a diameter of 2.
Evaluating the efficacy of Rho kinase inhibitor eye drops in the management of corneal edema: A single-center retrospective cohort study.
Taiwan J Ophthalmol
February 2024
Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Purpose: This study aimed to evaluate the efficacy of ripasudil in managing various corneal edema conditions.
Materials And Methods: This single-center retrospective analysis was conducted at Hadassah Medical Center and involved 16 patients with 17 eyes. Patients were selected based on diagnostic criteria, primarily corneal edema.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!